Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 2/20 | 0.54 |
| ▸ | FNTB | P49356 | 2/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353635 | 0.87 | FAAH (0.60) | KMT2AMEN1NPSR1FAAH | |
| SCHEMBL1704512 | 0.87 | ALDH1A1 (0.66) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24200046 | 0.86 | NPSR1 (0.58) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29132085 | 0.86 | SIGMAR1 (0.59) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4595454 | 0.85 | KMT2A (0.57) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24199876 | 0.85 | SIGMAR1 (0.68) | ALDH1A1LMNAHTTKDM4EFAAH | |
| SCHEMBL13150170 | 0.84 | KDM4E (0.60) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8642538 | 0.84 | MEN1 (0.59) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12018089 | 0.84 | KMT2A (0.56) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4188531 | 0.84 | KMT2A (0.52) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | KMT2A 3278/4885MEN1 3996/4885NPSR1 133/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | KMT2A 3208/4885MEN1 3015/4885NPSR1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.